Misplaced Pages

NNC2215

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Type of insulin

NNC2215 is a bioengineered glucose-sensitive insulin. The drug is designed by a team of Novo Nordisk researchers.

NNC2215 can sense the glucose concentration presence in blood. The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia. In addition, it can effectively cover the risk of fluctuations of blood sugar levels.

The study was published on scientific journal Nature on October 16, 2024. This study demonstrated the ability of protein engineering in future medicine and a major advancement in treatment capabilities.

History

A glucose sensitive treatment method for diabetes have long been pursued by science since 1979. Such protein is expected to solve the problem of fluctuations of blood sugar levels. For diabetes patients, skipping meal alone could lead to hypoglycemia, which is a common complication could cause loss of consciousness or seizures.

There are several attempts to create such a medicine with various levels of success.

See also

References

  1. PhD, Jonathan D. Grinstein (2024-10-21). "Novo Nordisk Researchers Engineer Glucose-Sensitive Insulin Switch". Inside Precision Medicine. Retrieved 2025-01-01.
  2. Kwon, Diana (2024-10-16). "'Smart' insulin prevents diabetic highs — and deadly lows". Nature. doi:10.1038/d41586-024-03357-7. PMID 39414970.
  3. Hoeg-Jensen, Thomas; Kruse, Thomas; Brand, Christian L.; Sturis, Jeppe; Fledelius, Christian; Nielsen, Peter K.; Nishimura, Erica; Madsen, Alice R.; Lykke, Lennart; Halskov, Kim S.; Koščová, Simona; Kotek, Vladislav; Davis, Anthony P.; Tromans, Robert A.; Tomsett, Michael (16 October 2024). "Glucose-sensitive insulin with attenuation of hypoglycaemia". Nature. 634 (8035): 944–951. Bibcode:2024Natur.634..944H. doi:10.1038/s41586-024-08042-3. ISSN 1476-4687. PMC 11499270. PMID 39415004.
  4. Brownlee, Michael; Cerami, Anthony (1979-12-07). "A Glucose-Controlled Insulin-Delivery System: Semisynthetic Insulin Bound to Lectin". Science. 206 (4423): 1190–1191. Bibcode:1979Sci...206.1190B. doi:10.1126/science.505005. PMID 505005.
  5. "Low Blood Glucose (Hypoglycemia) - NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 2025-01-01.
  6. Jarosinski, Mark A; Chen, Yen-Shan; Varas, Nicolás; Dhayalan, Balamurugan; Chatterjee, Deepak; Weiss, Michael A (2022-04-01). "New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals". The Journal of Clinical Endocrinology & Metabolism. 107 (4): 909–928. doi:10.1210/clinem/dgab849. ISSN 0021-972X. PMC 8947325. PMID 34850005.
  7. Liu, Yun; Wang, Shiqi; Wang, Zejun; Yu, Jicheng; Wang, Jinqiang; Buse, John B.; Gu, Zhen (2024-06-10). "Recent Progress in Glucose-Responsive Insulin". Diabetes. 73 (9): 1377–1388. doi:10.2337/dbi23-0028. ISSN 0012-1797. PMID 38857114.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: